COVAXIN™ (BBV152) Shows Demonstration of Protective Efficacy and Immunogenicity in Non-Human Primates
Disclaimer* – [Please read below]
SALIENT FEATURES –
- A 2-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally).
- One group was administered with placebo, while three groups were immunized with 3 different vaccine candidates at 0 and 14 days. All the macaques were exposed to viral challenge 14 days after the 2nd dose.
- The results showed protective efficacy, increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues of monkey.
- No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group
- Adverse events were not seen in animals immunized with a two-dose vaccination regimen.
To summarize, the vaccine candidate was found to generate robust immune responses. Thus, preventing infection and disease in the primates upon high amounts of exposure to live SARS-CoV-2 virus.
Kindly press this link for more info (https://doi.org/10.21203/rs.3.rs-65715/v1)
*Disclaimer: The provided study information is a preprint publish and has not yet undergone peer review. The findings are provisional and the conclusions/final results may differ.
Forward Looking Statement : [Download PDF]